Current clinical evidence supports the use of GLP-1 receptor agonists (GLP-1 RAs) in reducing cardiovascular events, including myocardial infarction, particularly in patients with type 2 diabetes and high cardiovascular risk. Here, GLP1R is linked to type 2 diabetes mellitus.